STUDIES OF CHLAMYDIA TRACHOMATIS

沙眼衣原体的研究

基本信息

项目摘要

C. trachomatis is the leading cause of bacerially-acquired sexually transmitted infections in the USA and is responsible for 25-50% of the estimate 1 million cases per year of pelvic inflammatory disease. Sequelae include ectopic pregnancy and sterility. To begin to dissect the destructive versus the protective response as well as identify potential vaccine candidates, our overall goal is to understand the cell and molecular biology of chlamydial antigen sorting and secretion in infected polarized human endometrial epithelial cells. We have detected escape of chlamydial LPS and the major outer membrane protein (MOMP) to the surface of infected cells prior to the natural release of chlamydiae at the end of the developmental cycle. Do chlamydial stress response proteins also escape to the infected cell surface: What pathway do these antigens take from the inclusion and how are the surface exposed antigens perceived by the host immune response: We shall use the powerful technique of post-embedding immunoelectron microscopy on Lowicryl-processed samples to determine in Specific Aim 1 if C. trachomatis serovar E GroEL and DnaK are also secreted to the surface of normally infected and penicillin and interferon gamma-induced persistently infected human endometrial epithelial cells, and in Specific Aim 2 to continue to assess whether or not chlamydial antigens are secreted in a polarized direction. Primary antibodies (ABY) directed against chlamydia specific histones will serve as a control marker for antigens which do not escape the inclusion and mABY directed against Class 1 molecules will serve as a marker for the basolateral domain. Digitized fluorescence microscopy of duplicate samples will give a more quantitative assessment of the pattern of directed antigen secretion. In Specific Aim 3, we shall investigate if chlamydial surface antigen secretion is modulated by estrogen and progesterone. Since the trans- golgi excytosis inhibitor Brefeldin A reduces escape of LPS and MOMP from inclusions, chlamydial antigens may exploit the secretory pathway to reach the infected cell surface. In Specific Aim 4, we shall analyze the pathway of chlamydial antigen sorting by co-localizing escaped chlamydial antigen with the golgi markers beta-COP, p58 and C6-NBD-ceramide. Finally, to begin to examine immune control of chlamydial growth, we have established an in vitro co-cultivation model to assess host effector PMN and T cell responses to infected human epithelial cells.
沙眼衣原体是细菌性获得性性病的主要原因 在美国传播的感染,占 25-50% 估计每年有 100 万例盆腔炎病例。 后遗症包括宫外孕和不孕。 开始剖析 破坏性反应与保护性反应以及识别潜在的 候选疫苗,我们的总体目标是了解细胞和 感染者衣原体抗原分选和分泌的分子生物学 极化的人子宫内膜上皮细胞。 我们检测到衣原体脂多糖和主要外膜的逃逸 蛋白质(MOMP)先于自然感染细胞表面 在发育周期结束时释放衣原体。 做 衣原体应激反应蛋白也逃逸至受感染的细胞 表面:这些抗原从包涵体中采取什么途径以及如何进行 是宿主免疫反应感知到的表面暴露抗原: 我们将使用强大的后嵌入免疫电子技术 对经过 Lowicryl 处理的样品进行显微镜检查,以确定特定目标 1 中是否 沙眼衣原体血清型 E GroEL 和 DnaK 也分泌到表面 正常感染以及青霉素和干扰素γ诱导的 持续感染的人子宫内膜上皮细胞,并且在特定情况下 目标 2 继续评估衣原体抗原是否 沿极化方向分泌。 一抗 (ABY) 定向 抗衣原体特异性组蛋白将作为对照标记 无法逃脱包涵体和针对的 mABY 的抗原 1 类分子将作为基底外侧域的标记。 重复样品的数字化荧光显微镜将提供更多信息 定向抗原分泌模式的定量评估。 在 具体目标3,我们将调查衣原体表面抗原是否 分泌受雌激素和孕激素调节。 自从跨 高尔基体胞吐作用抑制剂 Brefeldin A 可减少 LPS 和 MOMP 的逃逸 包涵体,衣原体抗原可能利用分泌途径到达 受感染的细胞表面。 在具体目标 4 中,我们将分析 通过共定位逃逸衣原体进行衣原体抗原分选途径 具有高尔基体标记 β-COP、p58 和 C6-NBD-神经酰胺的抗原。 最后,为了开始检查衣原体生长的免疫控制,我们有 建立体外共培养模型来评估宿主效应PMN 和 T 细胞对受感染的人类上皮细胞的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Priscilla B. Wyrick其他文献

Priscilla B. Wyrick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Priscilla B. Wyrick', 18)}}的其他基金

EFFICACY OF MICROBICIDES IN CHLAMYDIA TRACHOMATIS
杀菌剂对沙眼衣原体的功效
  • 批准号:
    6352614
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:
EVALUATION OF C31G VS NONOXYNOL-9 AS TOPICAL MICROBICIDES
C31G 与 NONOXYNOL-9 作为外用杀菌剂的评价
  • 批准号:
    6099894
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
EVALUATION OF C31G VS NONOXYNOL-9 AS TOPICAL MICROBICIDES
C31G 与 NONOXYNOL-9 作为外用杀菌剂的评价
  • 批准号:
    6235313
  • 财政年份:
    1997
  • 资助金额:
    --
  • 项目类别:
STUDIES OF CHLAMYDIA TRACHOMATIS
沙眼衣原体的研究
  • 批准号:
    6235018
  • 财政年份:
    1997
  • 资助金额:
    --
  • 项目类别:
VIRULENCE FACTORS OF CHLAMYDIAE
衣原体的毒力因子
  • 批准号:
    2059974
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
EFFICACY OF MICROBICIDES IN CHLAMYDIA TRACHOMATIS
杀菌剂对沙眼衣原体的功效
  • 批准号:
    6233362
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
VIRULENCE FACTORS OF CHLAMYDIAE
衣原体的毒力因子
  • 批准号:
    6372959
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
Virulence Factors of Chlamydiae
衣原体的毒力因子
  • 批准号:
    6913865
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
Virulence Factors of Chlamydiae
衣原体的毒力因子
  • 批准号:
    7588794
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:
VIRULENCE FACTORS OF CHLAMYDIAE
衣原体的毒力因子
  • 批准号:
    2059976
  • 财政年份:
    1995
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了